Research Findings on Nine GlaxoSmithKline Cancer Compounds to be Presented at...( Data Include First Presentation of Ph...),Health
Navigation Links
Research Findings on Nine GlaxoSmithKline Cancer Compounds to be Presented at ASCO 2009
Date:5/11/2009
Data Include First Presentation of Phase III Progression Free Survival Results for Pazopanib in Kidney Cancer
LONDON and PHILADELPHIA, May 11 /PRNewswire/ -- GlaxoSmithKline (GSK) Oncology announced that new clinical data from nine of its oncology molecules will be featured in various presentations at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando beginning May 29. The presentations cover GSK Oncology research in solid and blood tumor treatment, supportive care and prevention in an array of difficult to treat tumors including kidney cancer, advanced breast cancer, leukemia and prostate cancer.
The following investigational presentations reflect the broad spectrum of GSK-sponsored studies being presented at this year's ASCO Congress:
Kidney Cancer: New, pivotal Phase III data surrounding the GSK oral, investigational, angiogenesis/VEGF inhibitor, pazopanib. Also, Phase II data on GSK089, a new investigational compound with a MET/VEGFR2 mechanism of action.
- ORAL PRESENTATION: "A randomized, double-blind Phase III study of pazopanib in treatment naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC)." Dr. C. Sternberg, San Camillo and Forlanini Hospitals, Italy; Presentation on June 1.
- "A Phase II study of 2 dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillary renal carcinoma (PRC)." Dr. R. Srinivasan, National Cancer Institute; Poster presentation on May 31.
Gastric Cancer: Investigational Phase II study exploring GSK089 in gastric cancer.
- ORAL PRESENTATION: "Assessment of 2 dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study." Dr. M. A. Shah, Memorial-Slo
'/>"/>
| SOURCE GlaxoSmithKline Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. Stanford researchers find culprit in aging muscles that heal poorly
2. Children of depressed moms do better when dad is involved, SLU researcher finds
3. UCLA researchers identify markers that may predict diabetes in still-healthy people
4. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
5. New research shows how chronic stress worsens neurodegenerative disease course
6. New research explores newborn in-hospital weight loss
7. Research may unlock mystery of autisms origin in the brain
8. Bipolar disorder relapses halved by Melbourne researchers
9. HIVs impact in Zimbabwe explored in new research
10. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
11. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
Post Your Comments:
(Date:11/27/2009)..., , KELOWNA, BC, Nov. 27 /PRNewswire/ - Uplo...ady seeing prime time in wellness. A combination o...ed data upload are solving a long term concern ove...sible to accurately gauge and reward improved part...echnologies is one of the first wellness suppliers...
(Date:11/27/2009)..., , DALLAS, Nov. 27 /PRNewswire-USNewswire/...dical procedure only 25 years ago, solid organ tra...tion thanks to the extraordinary men and women who... Nov. 11. Leaders came together from medical cente...ary of Baylor Regional Transplant Institute (BRTI)...
(Date:11/27/2009)..., , ROCHESTER, N.Y., Nov. 27 /PRNewswire-US...ry health care provider and fortunately every year...e prevention. But do all vaccines boost immunity f...additional ,booster shots, needed to keep immunity...cs, the Journal of the American Academy of Pediatr...
(Date:11/27/2009)..., , KIBBUTZ SHAMIR, Israel, Nov. 27 /PRNewsw...sdaq: SHMR ) ( "Shamir" ), a leading provider of ...ic lens market, announced today that its board of ...an aggregate amount of US$ 10 million (approximate...9 representative rate of exchange), or approximate...
(Date:11/27/2009)...alking and cycling plus low-emission vehicles may ... , FRIDAY, Nov. 27 (HealthDay News) -- Enco...of using cars would offer much greater public heal...hicles, U.K. researchers have found. , The stud... alternative urban land transport scenarios for Lo...
Breaking Medicine News(10 mins):Health News:New USB technology adds accountability and convenience to wellness programs 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 3Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:More Foot Power, Less Car Pollution Best for Health 2[0] New USB technology adds accountability and convenience to wellness programs[0] Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary[0] Why Some Vaccines May Require A Booster[0] Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend[0] More Foot Power, Less Car Pollution Best for Health
...ioMarin Pharmaceutical,Inc. (Nasdaq: BMRN ) annou...Assessment Program (MorCAP) for patients with the ...pe IVA (MPS IVA), or Morquio A Syndrome. MorCAP is... expects to follow the MorCAP program with a Phase...
... Zon hearing aid, designed by,Stuart Karten Design...e,s,Design Award, presented by the Smithsonian,s C...per-Hewitt,s 9th annual National Design Awards gal...loping Zon, we sought to move the perception of th...
... 3 GeneThera, Inc.,(Pink Sheets: GTHR), As a serv...ra is publicly outlining our strategy for the futu...hift from a Research and Development,organization ...08) had been one of research only. We focused all,...
...Nov. 3 Cadient Group, the,premier strategic inter...ustry, announced today it has ranked 34th in Deloi...adelphia - a ranking of the 50 fastest-growing,tec...ations. Rankings are based on the percentage reven...
... BioCryst,Pharmaceuticals, Inc. (Nasdaq: BCRX ) ...and Chief Executive Officer of BioCryst, will pres...0th Annual Healthcare,Conference in New York on Mo...nk to a live audio Web cast of the presentation ma...
... 3 "When my father was formally,diagnosed with Al...pamphlet, and newspaper article I could get my han..."A Conversation About Alzheimer,s" (published by,A...I,could get the right physicians, no matter the co...
Other Medicine News:Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 2Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 3Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 4Health News:Stuart Karten Design's Zon Hearing Aid Wins 2008 Cooper-Hewitt People's Design Award 2Health News:Stuart Karten Design's Zon Hearing Aid Wins 2008 Cooper-Hewitt People's Design Award 3Health News:GeneThera - CHANGING DIRECTIONS - an Update to Shareholders 2Health News:GeneThera - CHANGING DIRECTIONS - an Update to Shareholders 3Health News:GeneThera - CHANGING DIRECTIONS - an Update to Shareholders 4Health News:GeneThera - CHANGING DIRECTIONS - an Update to Shareholders 5Health News:GeneThera - CHANGING DIRECTIONS - an Update to Shareholders 6Health News:Cadient Group Ranked 34th in Deloitte's Fast 50 Program for Greater Philadelphia 2Health News:BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference 2Health News:BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference 3Health News:'A Conversation About Alzheimer's': Woman Shares Story of Love, Hope, Loss and Survival in New Book About Alzheimer's Disease 2BioMarin Announces Initiation of Clinical Assessment Program for Morquio A SyndromeStuart Karten Design's Zon Hearing Aid Wins 2008 Cooper-Hewitt People's Design AwardGeneThera - CHANGING DIRECTIONS - an Update to ShareholdersCadient Group Ranked 34th in Deloitte's Fast 50 Program for Greater PhiladelphiaBioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference'A Conversation About Alzheimer's': Woman Shares Story of Love, Hope, Loss and Survival in New Book About Alzheimer's Disease
(Date:11/25/2009)..., , WESTON, Fla., Nov. 25 /PRNewswire...(Pink Sheets: ASFX) ("the Company") is pleased to ...g and production management office in Shanghai, Ch...abroad, providing an essential gateway for the dev...th and safety products for children and adults to ...
(Date:11/25/2009)..., , CHICAGO and STAFA, Switzerland, Nov. 25... leading manufacturer of innovative hearing soluti...are for Adults Conference, focusing on the special...ught together leading experts in aging and audiolo...ans who work everyday with older people with heari...
(Date:11/25/2009)..., , RANCHO CORDOVA, Calif., Nov. 25 /PRNews...ary of American Pacific Corporation (Nasdaq: APFC...tal Responsibility and Sustainability Award at the...by the California Manufacturers and Technology Ass...ciation (IEA) and the Chemical Industry Council of...
Breaking Medicine Technology:American Scientific Resources Inc. Opens Shanghai Location 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 3Census Bureau to Announce Findings for Income Earnings Poverty and Health Insurance Coverage 56596 1Census Bureau to Announce Findings for Income Earnings Poverty and Health Insurance Coverage 56596 2Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 1Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 2Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 3Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 4Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 5Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 6Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 7Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 8Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 9PDL BioPharma to Present at BioCentury Newsmakers Conference on September 16 2009 56592 1...achour, MD, FACC, director of interventional cardi... results of a study at the American Heart,Associat...lynews.com/tuesday.pdf ) meeting in Orlando showin...efore a heart attack,patient arrives improves door... after hours. Door-to-balloon time is measured fro...
... observed through 2.5 years of LymphoStat-...observed increase in rates of adverse events, seri...over 2.5 years of LymphoStat-B treatment -, ROCKV...daq: HGSI ) today announced the presentation of P...tat-B(R) (belimumab) achieved a sustained,improvem...
Other Medicine Technology:Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients 2Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus 7Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus 8| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |